Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-390 With Adalimumab

• Change from baseline in disease activity score (DAS28) [CRP] with baseline being Study M13-390 Week 0 Visit. [ Time Frame: Week 12 and Week 24 ] [ Designated as safety issue: No ]
• Response defined by American College of Rheumatology (ACR) 20/50/70/90/100 criteria with baseline being Study M13-390 Week 0 Visit. [ Time Frame: Week 12 and Week 24 ] [ Designated as safety issue: No ]
• Change from baseline in Health assessment Questionnaire (HAQ-DI) with baseline being Study M13-390 Week 0 Visit. [ Time Frame: Week 12 and Week 24 ] [ Designated as safety issue: No ]

Phase 2b,open label, multicenter study in rheumatoid arthritis for subjects who completed the previous M13-390 study.

Inclusion Criteria:

1. Subject has completed the preceding Study M13-390 for rheumatoid arthritis and has not developed any discontinuation criteria from that study.

2. If female, subject is either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy and/or hysterectomy) or is of childbearing potential and is practicing an approved method of birth control throughout the study and for 150 days after last dose of study drug. Examples of approved methods of birth control include the following (see local informed consent for more detail):

   • Condoms, sponge, foams, jellies, diaphragm or intrauterine device (IUD);
   • Hormonal contraceptives for 90 days prior to study drug administration;
   • A vasectomized partner;
3. Subjects must be able and willing to self-administer subcutaneous (SC) injections or have a qualified person available to administer SC injections.
4. Subject is judged to be in good general health as determined by the Principal Investigator based upon the results of medical history, physical examination, laboratory profile performed at Baseline.
5. Subjects must be able and willing to provide written informed consent and to comply with the requirements of this study protocol.

Exclusion Criteria:

1. Infection(s) requiring treatment with intravenous (IV) anti-infectives within 30 days prior to the Baseline Visit or oral anti-infectives within 14 days prior to the Baseline Visit.
2. Subject currently uses or plans to use anti-retroviral therapy at any time during the study.
3. Subject plans to use any live vaccine during the study.
4. Positive pregnancy test at Baseline (Week 0).
5. Subject is considered by the investigator, for any reason, to be an unsuitable candidate for the study.